Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

In-gel digestion for mass spectrometric characterization of proteins and proteomes

Shevchenko, A., Tomas, H., Havli, J., Olsen, J. V., & Mann, M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.468 · Cited by 4,947

Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips

Rappsilber, J., Mann, M., & Ishihama, Y. (2007) · Nature Protocols · doi:10.1038/nprot.2007.261 · Cited by 4,641

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286

Tumor-Associated Macrophages: From Mechanisms to Therapy

Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089

IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors

Zou, Y., Liu, B., Li, L., Yin, Q., Tang, J., Jing, Z., Huang, X., Zhu, X., & Chi, T. H. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.016 · Cited by 49

BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma

Yang, J., Zhou, W., Li, D., Niu, T., & Wang, W. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215949 · Cited by 51

Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer

Kandra, P., Nandigama, R., Eul, B. G., Huber, M., Kobold, S., Seeger, W., Grimminger, F., & Savai, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903562 · Cited by 50

Genetically Programmable Vesicles for Enhancing CAR‐T Therapy against Solid Tumors

Li, X., Zhu, T., Wang, R., Chen, J., Tang, L., Huo, W., Huang, X., & Cao, Q. (2023) · Advanced Materials · doi:10.1002/adma.202211138 · Cited by 49

Challenges and innovations in CAR-T cell therapy: a comprehensive analysis

Luo, J., & Zhang, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1399544 · Cited by 48

Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy

Ouladan, S., & Orouji, E. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02081 · Cited by 48

Adoptive T cell therapy: Boosting the immune system to fight cancer

León, E. C., Ranganathan, R., & Savoldo, B. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101437 · Cited by 48

Immunotherapy for the treatment of multiple myeloma

Boussi, L. S., Avigan, Z. M., & Rosenblatt, J. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1027385 · Cited by 48

Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy

Li, W., Pan, X., Chen, L., Cui, H., Mo, S., Pan, Y., Shen, Y., Shi, M., Wu, J., Luo, F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1186383 · Cited by 49

Immunotherapy of lymphomas

Ansell, S. M., & Lin, Y. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129206 · Cited by 48

αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib

Fang, J., Ding, N., Guo, X., Sun, Y., Zhang, Z., Xie, B., Zhong, L., Wang, H., Mao, W., Lin, Z., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001162 · Cited by 47

Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors

Matsumoto, Y., & Ju, T. (2023) · Cancers · doi:10.3390/cancers15143536 · Cited by 48

How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC

Chen, L., Jiang, X., Li, Y., Zhang, Q., Li, Q., Zhang, X., Zhang, M., Yu, Q., & Gao, D. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108962 · Cited by 46

Next Generation Natural Killer Cells for Cancer Immunotherapy

Rossi, F., Fredericks, N., Snowden, A., Allegrezza, M. J., & Moreno‐Nieves, U. Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.886429 · Cited by 47

Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker

Dacek, M. M., Kurtz, K. G., Wallisch, P., Pierre, S. A., Khayat, S., Bourne, C. M., Gardner, T. J., Vogt, K. C., Aquino, N., Younes, A., et al. (2023) · Blood · doi:10.1182/blood.2022016101 · Cited by 48

Mechanisms of and approaches to overcoming resistance to immunotherapy

Schultz, L. M., & Gardner, R. A. (2019) · Hematology · doi:10.1182/hematology.2019000018 · Cited by 45

T Cell Reprogramming Against Cancer

Katz, S. G., & Rabinovich, P. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-0716-0203-4_1 · Cited by 45

Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches

Gu, T., Zhu, M., Huang, H., & Hu, Y. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200256 · Cited by 45

Directed evolution of genetically encoded LYTACs for cell-mediated delivery

Yang, J. L., Yamada‐Hunter, S. A., Labanieh, L., Sotillo, E., Cheah, J. S., Roberts, D. S., Mackall, C. L., Bertozzi, C. R., & Ting, A. Y. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2320053121 · Cited by 45

Engineered Removal of PD-1 From the Surface of CD19 CAR-T Cells Results in Increased Activation and Diminished Survival

Kalinin, R. S., Ukrainskaya, V. M., Chumakov, S. P., Moysenovich, A. M., Tereshchuk, V. M., Volkov, D. V., Pershin, D., Maksimov, E. G., Zhang, H., Maschan, M. A., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.745286 · Cited by 44

Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer

Wang, Y., Han, J., Wang, D., Cai, M., Xu, Y., Hu, Y., Chen, H., He, W., & Zhang, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01646-7 · Cited by 43

Improving safety of cancer immunotherapy via delivery technology

Hu, D., Zhang, W., Tang, J., Zhou, Z., Liu, X., & Shen, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120407 · Cited by 43

Advances in Engineered Polymer Nanoparticle Tracking Platforms towards Cancer Immunotherapy—Current Status and Future Perspectives

Thangam, R., Patel, K. D., Kang, H., & Paulmurugan, R. (2021) · Vaccines · doi:10.3390/vaccines9080935 · Cited by 44

Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy

Singh, N., & Maus, M. V. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.010 · Cited by 44

Revving the CAR – Combination strategies to enhance CAR T cell effectiveness

Bansal, R., & Reshef, R. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100695 · Cited by 42

Targeted Delivery of CXCL9 and OX40L by Mesenchymal Stem Cells Elicits Potent Antitumor Immunity

Yin, P., Gui, L., Wang, C., Yan, J., Liu, M., Ji, L., Wang, Y., Ma, B., & Gao, W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.08.005 · Cited by 44

Development of CAR T Cell Therapy in Children—A Comprehensive Overview

Boettcher, M., Joechner, A., Li, Z., Yang, S. F., & Schlegel, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082158 · Cited by 42

Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors

Yan, T., Yu, L., Shangguan, D., Li, W., Liu, N., Chen, Y., Fu, Y., Tang, J., & Liao, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109638 · Cited by 45

Application of novel CAR technologies to improve treatment of autoimmune disease

Cheever, A., Kang, C., O'Neill, K. L., & Weber, K. S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1465191 · Cited by 41

Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors

Alcantara, M., du Rusquec, P., & Romano, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777064 · Cited by 43

Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis

Wang, H., Han, P., Qi, X., Li, F., Li, M., Fan, L., Zhang, H., Zhang, X., & Yang, X. (2021) · Cancers · doi:10.3390/cancers13020197 · Cited by 42

CAR-NK cells in combination therapy against cancer: A potential paradigm

Li, J., Hu, H., Lian, K., Zhang, D., Hu, P., He, Z., Zhang, Z., & Wang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27196 · Cited by 40

Strategies of Combination Drug Delivery for Immune Checkpoint Blockades

Ruan, H., Bu, L., Hu, Q., Cheng, H., Lu, W., & Gu, Z. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201801099 · Cited by 40

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

Petty, A. J., Heyman, B. M., & Yang, Y. (2020) · Cancers · doi:10.3390/cancers12040842 · Cited by 40

Design and Implementation of NK Cell-Based Immunotherapy to Overcome the Solid Tumor Microenvironment

Navin, I., Lam, M. T., & Parihar, R. (2020) · Cancers · doi:10.3390/cancers12123871 · Cited by 40

Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC

Harrasser, M., Gohil, S. H., Lau, H. E., Peruta, M. D., Muczynski, V., Patel, D., Miranda, E., Grigoriadis, K., Grigoriadis, A. E., Granger, D., et al. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01531-1 · Cited by 40

CAR-T Therapy in GBM: Current Challenges and Avenues for Improvement

Pant, A., & Lim, M. K. (2023) · Cancers · doi:10.3390/cancers15041249 · Cited by 39

Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodies

Najafi, S., & Mortezaee, K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122387 · Cited by 39

Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies

Huang, Y., Qin, Y., He, Y., Qiu, D., Zheng, Y., Wei, J., Zhang, L., Yang, D., & Li, Y. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101082 · Cited by 40

CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma

Pascual‐Pasto, G., McIntyre, B. C., Hines, M. G., Giudice, A. M., Garcia-Gerique, L., Hoffmann, J., Mishra, P., Matlaga, S., Lombardi, S., Shraim, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51337-2 · Cited by 40

Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype

Gargett, T., Truong, N. T., Ebert, L. M., Yu, W., & Brown, M. P. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.03.003 · Cited by 39

Molecular Imaging for Cancer Immunotherapy: Seeing Is Believing

Saeed, M., Xu, Z., Geest, B. G. D., Xu, H., & Yu, H. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00851 · Cited by 40

4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells

Dai, Q. G., Han, P., Qi, X., Li, F., Li, M., Fan, L., Zhang, H., Zhang, X., & Yang, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.539654 · Cited by 40

Engineered T Cells: CAR T Cell Therapy and Beyond

Johnson, P. C., & Abramson, J. S. (2022) · Current Oncology Reports · doi:10.1007/s11912-021-01161-4 · Cited by 39

Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer

Rossetti, R., Brand, H., de Lima, S. C. G., Furtado, I. P., Silveira, R. M., Fantacini, D. M. C., Covas, D. T., & de Souza, L. E. B. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac005 · Cited by 40

Tumors evading CARs—the chase is on

Rafiq, S., & Brentjens, R. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0212-6 · Cited by 39

Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels

Lv, J., Qin, L., Zhao, R., Wu, D., Wu, Z., Zheng, D., Li, S., Luo, M., Wu, Q., Long, Y., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.12.003 · Cited by 38

Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology

Mylvaganam, G., Yanez, A. G., Maus, M. V., & Walker, B. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02109 · Cited by 38

The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers

Wang, G., Tai, R., Wu, Y., Yang, S., Wang, J., Yu, X., Lei, L., Shan, Z., & Li, N. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.02.002 · Cited by 38

CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy

Huang, D., Miller, M., Ashok, B., Jain, S., & Peppas, N. A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.015 · Cited by 38

Rationally designed approaches to augment CAR-T therapy for solid tumor treatment

Zhu, C., Wu, Q., Sheng, T., Shi, J., Shen, X., Yu, J., Du, Y., Sun, J., Liang, T., He, K., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.11.002 · Cited by 39

Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy

Russell, B., & Avigan, D. (2023) · International journal of hematology · doi:10.1007/s12185-023-03579-x · Cited by 36

Challenges and solutions for therapeutic TCR ‐based agents

Malviya, M., Aretz, Z. E. H., Molvi, Z., Lee, J., Pierre, S. A., Wallisch, P., Dao, T., & Scheinberg, D. A. (2023) · Immunological Reviews · doi:10.1111/imr.13233 · Cited by 37

Payload-delivering engineered γδ T cells display enhanced cytotoxicity, persistence, and efficacy in preclinical models of osteosarcoma

Fowler, D. W., Barisa, M., Southern, A., Nattress, C. B., Hawkins, E., Vassalou, E., Kanouta, A., Counsell, J. R., Miranda, E., Vlckova, P., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg9814 · Cited by 37

Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins

Klesmith, J. R., Su, L., Wu, L., Schrack, I. A., Dufort, F. J., Birt, A., Ambrose, C. M., Hackel, B. J., Lobb, R. R., & Rennert, P. D. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00418 · Cited by 37

T‐cells expressing a chimeric‐PD1‐Dap10‐CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer

Parriott, G., Deal, K., Crean, S., Richardson, E., Nylen, E., & Barber, A. E. (2020) · Immunology · doi:10.1111/imm.13187 · Cited by 37

The dark side of immunotherapy: pancreatic cancer

Mucciolo, G., Roux, C., Scagliotti, A., Brugiapaglia, S., Novelli, F., & Cappello, P. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.13 · Cited by 38

Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?

Jiang, H., Hu, Y., & Mei, H. (2020) · Biomarker Research · doi:10.1186/s40364-020-00247-8 · Cited by 38

Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition

Yeku, O., Rao, T. D., Laster, I., Kononenko, A. P., Purdon, T. J., Wang, P., Cui, Z., Liu, H., Brentjens, R. J., & Spriggs, D. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663379 · Cited by 37

Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma

Gray, S. G. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01513-7 · Cited by 37

Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy

Frlic, T., & Pavlin, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1688995 · Cited by 38

Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma

Shu, C., & Li, Q. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102965 · Cited by 36

Anti‐tumor efficacy of human anti‐c‐met CAR‐T cells against papillary renal cell carcinoma in an orthotopic model

Mori, J., Adachi, K., Sakoda, Y., Sasaki, T., Goto, S., Matsumoto, H., Nagashima, Y., Matsuyama, H., & Tamada, K. (2021) · Cancer Science · doi:10.1111/cas.14835 · Cited by 37

Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring

Shao, F., Long, Y., Ji, H., Jiang, D., Lei, P., & Lan, X. (2021) · Theranostics · doi:10.7150/thno.56989 · Cited by 36

Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?

Guedan, S., Luu, M., Ammar, D., Barbao, P., Bonini, C., Bousso, P., Buchholz, C. J., Casucci, M., Angelis, B. D., Donnadieu, E., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003487 · Cited by 38

Genetically modified immune cells targeting tumor antigens

Poorebrahim, M., Abazari, M. F., Sadeghi, S., Mahmoudi, R., Kheirollahi, A., Askari, H., Wickström, S. L., Poortahmasebi, V., Lundqvist, A., Kiessling, R. W., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107603 · Cited by 36

Emerging strategies for treating autoimmune disorders with genetically modified Treg cells

Boardman, D. A., & Levings, M. K. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.11.007 · Cited by 36

CAR‐T‐cell products in solid tumors: Progress, challenges, and strategies

Qian, K., Li, G., Zhang, S., Fu, W., Li, T., Zhao, J., Lei, C., Wang, Y., & Hu, S. (2024) · Interdisciplinary medicine · doi:10.1002/inmd.20230047 · Cited by 36

Future of CAR T cells in multiple myeloma

Wudhikarn, K., Mailankody, S., & Smith, E. L. (2020) · Hematology · doi:10.1182/hematology.2020000111 · Cited by 35

Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma

Yuti, P., Sawasdee, N., Natungnuy, K., Rujirachaivej, P., Luangwattananun, P., Sujjitjoon, J., & Yenchitsomanus, P. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115691 · Cited by 36

Overcoming solid-tumor barriers: armored CAR-T cell therapy

Kwon, N., & Chen, Y. Y. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.009 · Cited by 33

Sense-and-Respond Payload Delivery Using a Novel Antigen-Inducible Promoter Improves Suboptimal CAR-T Activation

Guo, T., Ma, D., & Lu, T. K. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00236 · Cited by 33

Genetic enhancement: an avenue to combat aging-related diseases

Cai, Y., Ji, Z., Wang, S., Zhang, W., Qu, J. T., Belmonte, J. C. I., & Liu, G. (2022) · Life Medicine · doi:10.1093/lifemedi/lnac054 · Cited by 33

Biomaterials promote in vivo generation and immunotherapy of CAR-T cells

Qin, Y., Li, Y., He, X., Wang, X., Li, W., & Zhang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1165576 · Cited by 35

Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes

Marotte, L., Simon, S., Vignard, V., Dupre, E., Gantier, M., Cruard, J., Alberge, J.-B., Hussong, M., Deleine, C., Heslan, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000311 · Cited by 32

CAR T Cell Therapy Progress and Challenges for Solid Tumors

Stern, L. A., Jönsson, V. D., & Priceman, S. J. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_11 · Cited by 32

Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors

Yuan, X., Sun, Z., Yuan, Q., Hou, W., Liang, Q., Wang, Y.-X., Mo, W., Wang, H., & Yu, M. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00978-3 · Cited by 32

Contextual Reprogramming of CAR-T Cells for Treatment of HER2+ Cancers

Yang, Z., Li, L., Turkoz, A., Chen, P., Harari-Steinfeld, R., Bobbin, M. L., Stefanson, O., Choi, H., Pietrobon, V., Alphson, B., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-021-03132-6 · Cited by 32

Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?

Buechner, J., Caruana, I., Künkele, A., Rives, S., Vettenranta, K. K., Bader, P., Peters, C., Baruchel, A., & Calkoen, F. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2021.784024 · Cited by 32

Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer

Ge, Y., Zhang, Y., Zhao, K., & Zhu, H. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s374672 · Cited by 32

Four challenges to CAR T cells breaking the glass ceiling

Bailey, S. R., Berger, T. R., Graham, C., Larson, R. C., & Maus, M. V. (2022) · European Journal of Immunology · doi:10.1002/eji.202250039 · Cited by 34

Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation

Yu, J., Kong, X., & Feng, Y. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.14 · Cited by 32

Externally-Controlled Systems for Immunotherapy: From Bench to Bedside

Tristán‐Manzano, M., Justicia-Lirio, P., Maldonado‐Pérez, N., Cortijo-Gutierréz, M., Benabdellah, K., & Martı́n, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02044 · Cited by 32

CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials

Chintala, N. K., Restle, D. J., Quach, H. T., Saini, J. K., Bellis, R. Y., Offin, M. D., Beattie, J., & Adusumilli, P. S. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.05.004 · Cited by 31

The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas

Garcia-Lacarte, M., Grijalba, S. C., Melchor, J., Arnaiz-Leché, A., & Roa, S. (2021) · Cancers · doi:10.3390/cancers13184683 · Cited by 32

Anti-BCMA novel therapies for multiple myeloma

Sammartano, V., Franceschini, M., Fredducci, S., Caroni, F., Ciofini, S., Pacelli, P., Bocchia, M., & Gozzetti, A. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.138 · Cited by 32

A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor

Reichenbach, P., Attianese, G. M. P. G., Ouchen, K., Cribioli, E., Triboulet, M. M., Ash, S., Saillard, M., de Silly, R. V., Coukos, G., & Irving, M. B. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01013-5 · Cited by 32

Targeting autophagy overcomes cancer‐intrinsic resistance to CAR‐T immunotherapy in B‐cell malignancies

Tang, L., Zhang, H., Zhou, F., Wei, Q., Du, M., Wu, J., Li, C., Luo, W., Zhou, J., Wang, X., et al. (2024) · 癌症：英文版 · doi:10.1002/cac2.12525 · Cited by 33

CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside

Zhu, X., Xue, J., Jiang, H., & Xue, D. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02151-3 · Cited by 31

Engineering the next generation of CAR T- cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance

García-Robledo, J. E., Cabrera-Salcedo, S. C., Brandauer, A. M., Romano, F., Rengifo-Martinez, J., Toro-Pedroza, A., Hincapie, J. S. V., Ríos-Serna, L. J., Loukanov, A. R., Cardona, A. F., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1698442 · Cited by 32

Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy

Wang, E., Cesano, A., Butterfield, L. H., & Marincola, F. M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001619 · Cited by 30

Lentiviral delivery of combinatorial CAR/CRISPRi circuit into human primary T cells is enhanced by TBK1/IKKɛ complex inhibitor BX795

Li, L., Gao, Y., Srivastava, R., Wang, W., Xiong, Q., Fang, Z., Pelayo, A., Denson, C. R., Goswami, A., Harari-Steinfeld, R., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02526-2 · Cited by 30

The making and function of CAR cells

Zabel, M., Tauber, P. A., & Pickl, W. F. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.06.002 · Cited by 30

Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer

Hu, C., Liu, M., Li, Y., Zhao, Y., Sharma, A., Liu, H., & Schmidt‐Wolf, I. G. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213716 · Cited by 30

Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery

Gardner, T. J., Bourne, C. M., Dacek, M. M., Kurtz, K. G., Malviya, M., Peraro, L., Silberman, P. C., Vogt, K. C., Unti, M. J., Brentjens, R. J., et al. (2020) · Cancers · doi:10.3390/cancers12082175 · Cited by 29

Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies

Beider, K., Itzhaki, O., Schachter, J., Grushchenko-Polaq, A. H., Voevoda-Dimenshtein, V., Rosenberg, E., Ostrovsky, O., Devillers, O., Frommer, R. S., Zeltzer, L., et al. (2022) · Cells · doi:10.3390/cells11071140 · Cited by 30

4-1BB-Based CAR T Cells Effectively Reverse Exhaustion and Enhance the Anti-Tumor Immune Response through Autocrine PD-L1 scFv Antibody

Cheng, K., Feng, X., Chai, Z., Wang, Z., Liu, Z., Yan, Z., Wang, Y., & Zhang, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044197 · Cited by 29

Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective

Ho, C., Chen, H., Hu, R., & Lee, P. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919843463 · Cited by 29

Nanomaterials Boost CAR‐T Therapy for Solid Tumors

Long, J., Wang, Y., Jiang, X., Ge, J., Chen, M., Zheng, B., Wang, R., Wang, M., Xu, M., Qi, K., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304615 · Cited by 28

Abstract 2568: CAR T cells secreting an immune checkpoint blockade scFv have enhanced anti-tumor efficacy

Rafiq, S., Yeku, O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Yan, S., Wang, P., Xiang, J., Liu, C., Seshan, V., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-2568

Enhancing CAR T Cell Anti-Tumor Efficacy through Secreted Single Chain Variable Fragment (scFv) Immune Checkpoint Blockade

Rafiq, S., Jackson, H. J., Yeku, O., Purdon, T. J., van Leeuwen, D. G., Curran, K. J., Ahmed, R. N., Cullen, G. D., Yan, S., Wang, P., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.842.842 · Cited by 6

Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv

Yü, P., Li, F., Nan, S., Zhang, D., Shi, X., Shan, J., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00803 · Cited by 51

PD-1–Blocking scFV–Secreting CAR T Cells Exhibit Antitumor Efficacy

(2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2018-143

Improved survival of chimeric antigen receptor‐engineered T ( CAR ‐T) and tumor‐specific T cells caused by anti‐programmed cell death protein 1 single‐chain variable fragment‐producing CAR ‐T cells

Nakajima, M., Sakoda, Y., Adachi, K., Nagano, H., & Tamada, K. (2019) · Cancer Science · doi:10.1111/cas.14169 · Cited by 53